<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597502</url>
  </required_header>
  <id_info>
    <org_study_id>TC-0203</org_study_id>
    <nct_id>NCT04597502</nct_id>
  </id_info>
  <brief_title>The Effects of Terminalia Chebula Fruit Extract on the Gut Microbiome and Skin Biophysical Properties</brief_title>
  <official_title>&quot;The Effects of Synastol TC (Standardized Terminalia Chebula Fruit Extract) on the Gut Microbiome and Skin Biophysical Properties&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integrative Skin Science and Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sytheon Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Integrative Skin Science and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the use of oral Terminalia chebula fruit extract on&#xD;
      the gut microbiome and skin biophysical properties. The fruit is commonly used for skin&#xD;
      treatments in India. It is thought to have antioxidant properties, reduce inflammation and&#xD;
      affect the microorganisms in the gut.&#xD;
&#xD;
      The information the investigators will learn from this study may indicate how and if oral&#xD;
      dosing can affect the skin and gut microbiome. This may lead to an improved understanding of&#xD;
      the skin and determine whether these oral products are effective for improving the skin's&#xD;
      appearance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blinded placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Stool microbiome diversity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Stool is collected and analyzed for species of bacteria through nucleic acid sequencing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sebum production</measure>
    <time_frame>8 weeks</time_frame>
    <description>Delfin Sebumeter: 0-150 micrograms/cm^2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transepidermal water loss</measure>
    <time_frame>8 weeks</time_frame>
    <description>Delfin Vapometer 0-300g/m^2h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial pigmentation</measure>
    <time_frame>8 weeks</time_frame>
    <description>SkinColorCatchRGB range: 25-246 per channel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial redness - Device Based</measure>
    <time_frame>8 weeks</time_frame>
    <description>SkinColorCatch colorimeter RGB range: 25-246 per channel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial wrinkles</measure>
    <time_frame>8 weeks</time_frame>
    <description>BTBP Clarity Mini 3D camera: Wrinkle severity (depth and width measurement in unitless units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial shine</measure>
    <time_frame>8 weeks</time_frame>
    <description>BTBP Clarity Mini 3D: (Surface reflection measured in unitless units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hand and arm pigmentation</measure>
    <time_frame>8 weeks</time_frame>
    <description>SkinColorCatch colorimeter RGB range: 25-246 per channel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hand and arm redness</measure>
    <time_frame>8 weeks</time_frame>
    <description>SkinColorCatch colorimeter RGB range: 25-246 per channel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Topical Products</measure>
    <time_frame>8 weeks</time_frame>
    <description>Subjective Tolerability Questionnaire is collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin typing questionnaire</measure>
    <time_frame>8 weeks</time_frame>
    <description>Subjective Questionnaire is collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ayurvedic typing questionnaire</measure>
    <time_frame>8 weeks</time_frame>
    <description>Subjective Questionnaire is collected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Salivary diurnal cortisol slope</measure>
    <time_frame>8 weeks</time_frame>
    <description>4 point salivary cortisol is measured over the course of a day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Hydration</measure>
    <time_frame>8 weeks</time_frame>
    <description>Delfin MoisturemeterSC 0-150</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial Redness - Image Based</measure>
    <time_frame>8 weeks</time_frame>
    <description>BTBP Clarity Mini 3D camera</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Human Microbiome</condition>
  <arm_group>
    <arm_group_label>Oral Placebo, Topical Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Placebo, Topical Placebo on both forearms and dorsal hands</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Placebo, Topical TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Placebo, Topical TC on both forearms and dorsal hands</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral TC, Topical Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral TC, Topical Placebo on both forearms and dorsal hands</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral TC, Topical TC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral TC, Topical TC on both forearms and dorsal hands</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Terminalia Chebula fruit extract</intervention_name>
    <description>Oral TC fruit extract supplement taken by mouth twice per day</description>
    <arm_group_label>Oral TC, Topical Placebo</arm_group_label>
    <arm_group_label>Oral TC, Topical TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo taken by mouth twice per day</description>
    <arm_group_label>Oral Placebo, Topical Placebo</arm_group_label>
    <arm_group_label>Oral Placebo, Topical TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical Terminalia Chebula</intervention_name>
    <description>Applied to both forearms and dorsal hands</description>
    <arm_group_label>Oral Placebo, Topical TC</arm_group_label>
    <arm_group_label>Oral TC, Topical TC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical Placebo</intervention_name>
    <description>Applied to both forearms and dorsal hands</description>
    <arm_group_label>Oral Placebo, Topical Placebo</arm_group_label>
    <arm_group_label>Oral TC, Topical Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females aged 25 to 55 years of age&#xD;
&#xD;
          2. Subject must be able to read and comprehend study procedures and consent forms.&#xD;
&#xD;
          3. BMI 25-35&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects must have no history of malignancy, kidney disease, or chronic steroid use.&#xD;
&#xD;
          2. No history of smoking or chewing tobacco or vaping nicotine based products within the&#xD;
             past year or if the pack-year history of smoking tobacco is greater than 5 pack-years.&#xD;
&#xD;
          3. No history of anorexia&#xD;
&#xD;
          4. Those that are currently taking serotonin or SSRIs.&#xD;
&#xD;
          5. No intake of pomegranate containing drinks, walnuts, and strawberries two weeks prior&#xD;
             to enrollment and throughout the study&#xD;
&#xD;
          6. Those who are unable to discontinue topical medications for two weeks.&#xD;
&#xD;
          7. Individuals who have had any medical or cosmetic procedure, such as laser resurfacing,&#xD;
             or plastic surgery to the test site (face) within the last 6 months. This includes&#xD;
             botulinum toxin, dermal fillers, collagen or other similar cosmetic procedure&#xD;
&#xD;
          8. Individuals who are currently using or during the past 30 days have used hydroquinone,&#xD;
             or a retinoid such as Retin A, or other Rx/OTC Retinoid, or steroids.&#xD;
&#xD;
          9. Those who are unable to discontinue systemic antibiotics or oral probiotics for one&#xD;
             month prior starting the study.&#xD;
&#xD;
         10. Those who are unable to discontinue their Triphala or Terminalia chebula regimen for&#xD;
             one month prior to starting study.&#xD;
&#xD;
         11. Subjects who are postmenopausal or perimenopausal as determined by the investigator&#xD;
             based on history or documented menopause&#xD;
&#xD;
         12. Males will be excluded to reduce the contribution from gender-based differences in&#xD;
             testosterone which can affect sebum production on the face.&#xD;
&#xD;
         13. Those who are pregnant or breastfeeding&#xD;
&#xD;
         14. Those that are prisoners or cognitively impaired&#xD;
&#xD;
         15. Those who have a known allergy to Triphala or Terminalia chebula&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raja K Sivamani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Integrative Skin Science and Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raja Sivamani, MD</last_name>
    <phone>9165241216</phone>
    <email>research@integrativeskinresearch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Integrative Skin Science and Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raja K Sivamani, MD</last_name>
      <phone>916-524-1216</phone>
      <email>raja.sivamani@integrativeskinresearch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gut microbiome</keyword>
  <keyword>skin</keyword>
  <keyword>dermatology</keyword>
  <keyword>terminalia chebula</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

